TP53 and prostate cancer: applied 10X Visium on two adjacent sections from 10‐week RPM (Rb1−/−; Trp53−/−; cMyc+) mouse prostate cancer models, building on Ku et al.’s141 findings that Rb1 and Trp53 loss promotes lineage plasticity and antiandrogen resistance.